The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
about
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challengesGenetic Polymorphisms of CCL22 and CCR4 in Patients with Lung Cancer.Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cellsImmune cell recruitment and cell-based system for cancer therapy.Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.Detrimental role of CC chemokine receptor 4 in murine polymicrobial sepsis.Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.Humanized tumor mice--a new model to study and manipulate the immune response in advanced cancer therapy.Antibody therapy for Adult T-cell leukemia-lymphoma.A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide.Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF.No effect of humanized CCR monoclonal antibody (mogamulizumab) on treatment-resistant adult T cell leukemia with meningeal infiltration.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.
P2860
Q26866236-79C5681B-064C-41A0-9201-4A5704B3F64EQ33907317-D8B9017F-0DC8-4D86-9017-A5D4CF21F246Q33982582-939BE91B-05CB-4B91-86AD-FE02D9CCD51AQ36288217-CD999361-6F81-4DD0-ADDF-E7F86264BE50Q36392832-7C24EAB1-C93F-4F9B-9B94-82646E0045F7Q36517706-CB6A8F72-9E55-4A6F-9E97-4BF7139B7543Q36617341-AD640621-10A5-43FE-86E8-2226F37CD549Q36949926-9590106D-C274-48D7-B00B-738CC7F4A4B0Q38286374-B8D2F5E8-CF99-4C8C-9C0F-793ADA83EA65Q38982777-657378B8-0791-4C42-AEB8-174D50C48803Q39337108-A9B8FA6A-62A2-4DFA-8041-30B10D2AB596Q39547654-9298A479-1563-4849-8639-2B432237D158Q39698098-08FEE67D-B47E-41E5-B1BB-FDB42977E9BBQ42141309-381E9EB0-24DE-42DB-A3C8-CB10B4443B4BQ43078116-8E49705C-64E2-49C1-97AD-B4D27C840B55Q44391545-ABE6CD4D-D9C9-4CF6-A350-4E9F81CCB9D8Q49539698-134F91A6-B9A5-4B8B-B131-E2D3A52E09E8
P2860
The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
@en
type
label
The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
@en
prefLabel
The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
@en
P2093
P2860
P356
P1433
P1476
The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
@en
P2093
Kusumoto S
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404415
P577
2006-10-12T00:00:00Z
P5875
P6179
1017583112